Teladoc Health, Inc. (TDOC)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Teladoc Health, Inc. ("Teladoc" or the "Company") (NASDAQ: AMGN). Investors who purchased Teladoc securities are encouraged to obtain additional information and assist the investigation.     


The investigation concerns whether Teladoc and certain of its officers and/or directors have violated federal securities laws.


On April 27, 2022, Teladoc announced its first quarter 2022 financial results, including revenue of $565.4 million, which missed consensus estimates by $3.23 million, and “[n]et loss per share of $41.58, primarily driven by [a] non-cash goodwill impairment charge of $6.6 billion or $41.11 per share[,]” prompting multiple analyst downgrades on the Company’s stock.  On this news, Teladoc’s stock price fell sharply during intraday trading on April 28, 2022.


If you are aware of any facts relating to this investigation or purchased Teladoc shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.